Drug Trial Radar · NCT06970847
64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer
Last checked: Nov 20, 2026Latest source record: May 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
220
Planned (sponsor's estimate)
Start
May 16, 2025
Primary completion
Dec 31, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Clarity Pharmaceuticals LtdIndustry
- Sponsor type
- Industry
- First posted
- May 14, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim for this study is to investigate the ability of 64Cu-SAR-bisPSMA PET/CT to detect recurrence of prostate cancer
Conditions
- Prostate Cancer
- Prostate Cancer Patients With Detectable PSA Following Prostatectomy
- Prostate Cancer Recurrent
- Prostate Cancer Patients Who Have Brachytherapy Seed Implant
- Prostate Cancer Patients Treated by Radiotherapy
- Cryotherapy
Interventions
64Cu-SAR-bisPSMADrug
All Patients will receive a single administration, a bolus injection of 200MBq 64Cu-SAR-bisPSMA
Primary outcomes
What the sponsor says the trial is designed to measure.
- Ability of 64Cu-SAR-bisPSMA PET/CT to detect recurrence of prostate cancerTime frame: Up to 52 Weeks
Locations
22 sites in 2 countries. Site status is shown where the registry gives one.
UC Irvine
Irvine, California
Comprehensive Urology Medical Group
Los Angeles, California
Alarcon Urology Center
Montebello, California
Biogenix Molecular
Miami, Florida
Endeavor Health- Glenbrook Hospital
Glenview, Illinois
Indiana University Health-IU Simon Cancer Center
Indianapolis, Indiana
XCancer Research Network / LCMC Health EJGH
Metairie, Louisiana
M. Health Fairview University of Minnesota Medical Center
Minneapolis, Minnesota
St. Louis University
St Louis, Missouri
XCancer
Omaha, Nebraska
Albany Medical College
Albany, New York
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania
Carolina Urologic Research Center
Myrtle Beach, South Carolina
Urology Associates, P.C.
Nashville, Tennessee
Urology Clinics of North Texas
Dallas, Texas
The Urology Place
San Antonio, Texas
Summit Urology
Murray, Utah
Intermountain Medical Center
Salt Lake City, Utah
St. Vincent's Hospital, Sydney
Darlinghurst, New South Wales, Australia
Sydney Adventist Hospital
Wahroonga, New South Wales, Australia
Westmead Private Hosptial
Westmead, New South Wales, Australia
Royal Brisbane and Women's Hospital
Herston, Queensland, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.